Back to results
US 2014/0193445 A1Published application
Truncated Secretory Aspartyl Proteinase 2
AssigneesIstituto Superiore di Sanita, Pevion Biotech Ltd.
InventorsRinaldo Zurbriggen, Flavia De Bernardis, Antonio Cassone, Silvia Rasi
Life of this patent
Estimating the term…
Abstract
The present invention relates to an isolated truncated form of the secretory aspartyl proteinase 2, as well as to nucleic acid molecules encoding same. The present invention also relates to a composition comprising an isolated truncated form of the secretory aspartyl proteinase 2, as well as to nucleic acid molecules encoding same.
Claims25
An isolated polypeptide comprising an amino acid sequence selected from the group consisting of:
- (a) the amino acid sequence of SEQ ID NO:1;
- and,
- (b) a fragment of the amino acid sequence of SEQ ID NO:1, wherein the fragment is at least 15 amino acids in length, and wherein the fragment is functionally equivalent to the polypeptide having the amino acid sequence of SEQ ID NO:1;
- wherein the isolated polypeptide does not have the amino acid sequence of SEQ ID NO:3 or SEQ ID NO:7.
1 more element
An isolated polynucleotide comprising a nucleic acid sequence selected from the group consisting of:
- (a) the nucleic acid sequence of SEQ ID NO:2;
- (b) a nucleic acid sequence which is complementary to the nucleic acid sequence of SEQ ID NO:2;
- (c) a nucleic acid sequence which encodes the amino acid sequence of SEQ ID NO:1;
- and,
- (d) a fragment of the nucleic acid sequence of SEQ ID NO:2, wherein the fragment is at least 45 nucleotides in length, and wherein the fragment encodes a polypeptide that is functionally equivalent to the polypeptide having the amino acid sequence of SEQ ID NO:1;
- wherein the isolated polynucleotide does not have the nucleic acid sequence of SEQ ID NO:4 or SEQ ID NO:8.
3 more elements
A vaccine composition comprising at least one compound selected from the group consisting of:
- an isolated polypeptide comprising an amino acid sequence selected from the group consisting of:
- (a) the amino acid sequence of SEQ ID NO:1;
- and,
- (b) a fragment of the amino acid sequence of shown in SEQ ID NO:1, wherein the fragment is at least 15 amino acids in length, and wherein the fragment is functionally equivalent to the polypeptide having the amino acid sequence of SEQ ID NO:1;
- wherein the isolated polypeptide does not have the amino acid sequence of SEQ ID NO:3 or SEQ ID NO:7, and
- an isolated polynucleotide comprising a nucleic acid sequence selected from the group consisting of
- (a) the nucleic acid sequence of SEQ ID NO:2;
- (b) a nucleic acid sequence which is complementary to the nucleic acid sequence of SEQ ID NO:2;
- (c) a nucleic acid sequence which encodes the amino acid sequence of SEQ ID NO:1;
- and,
- (d) a fragment of the nucleic acid sequence of SEQ ID NO:2, wherein the fragment is at least 45 nucleotides in length, and wherein the fragment encodes a polypeptide that is functionally equivalent to the polypeptide having the amino acid sequence of SEQ ID NO:1;
- wherein the isolated polynucleotide does not have the nucleic acid sequence shown in SEQ ID NO:4 or SEQ ID NO:8.
9 more elements
A method of treating or preventing Candida infection in a mammal in need thereof, the method comprising administering to the mammal a pharmaceutical composition comprising at least one compound selected from the group consisting of:
- an isolated polypeptide comprising an amino acid sequence selected from the group consisting of:
- (a) the amino acid sequence of SEQ ID NO:1;
- and,
- (b) a fragment of the amino acid sequence of shown in SEQ ID NO:1, wherein the fragment is at least 15 amino acids in length, and wherein the fragment is functionally equivalent to the polypeptide having the amino acid sequence of SEQ ID NO:1;
- wherein the isolated polypeptide does not have the amino acid sequence of SEQ ID NO:3 or SEQ ID NO:7, and
- an isolated polynucleotide comprising a nucleic acid sequence selected from the group consisting of
- (a) the nucleic acid sequence of SEQ ID NO:2;
- (b) a nucleic acid sequence which is complementary to the nucleic acid sequence of SEQ ID NO:2;
- (c) a nucleic acid sequence which encodes the amino acid sequence of SEQ ID NO:1, and,
- (d) a fragment of the nucleic acid sequence of SEQ ID NO:2, wherein the fragment is at least 45 nucleotides in length, and wherein the fragment encodes a polypeptide that is functionally equivalent to the polypeptide having the amino acid sequence of SEQ ID NO:1;
- wherein the isolated polynucleotide does not have the nucleic acid sequence shown in SEQ ID NO:4 or SEQ ID NO:8.
8 more elements
A kit comprising at least one compound selected from the group consisting of:
- an isolated polypeptide comprising an amino acid sequence selected from the group consisting of:
- (a) the amino acid sequence of SEQ ID NO:1;
- and
- (b) a fragment of the amino acid sequence of shown in SEQ ID NO:1, wherein the fragment is at least 15 amino acids in length, and wherein the fragment is functionally equivalent to the polypeptide having the amino acid sequence of SEQ ID NO:1;
- wherein the isolated polypeptide does not have the amino acid sequence of SEQ ID NO:3 or SEQ ID NO:7, and
- an isolated polynucleotide comprising a nucleic acid sequence selected from the group consisting of
- (a) the nucleic acid sequence of SEQ ID NO:2;
- (b) a nucleic acid sequence which is complementary to the nucleic acid sequence of SEQ ID NO:2;
- (c) a nucleic acid sequence which encodes the amino acid sequence of SEQ ID NO:1;
- and,
- (d) a fragment of the nucleic acid sequence of SEQ ID NO:2, wherein the fragment is at least 45 nucleotides in length, and wherein the fragment encodes a polypeptide that is functionally equivalent to the polypeptide having the amino acid sequence of SEQ ID NO:1;
- wherein the isolated polynucleotide does not have the nucleic acid sequence shown in SEQ ID NO:4 or SEQ ID NO:8.
9 more elements
A method of performing an in vitro diagnosis of a Candida infection in a mammal using a kit, the method comprising contacting a biological sample from the mammal with a reagent from the kit, wherein the kit comprises at least one compound selected from the group consisting of:
- an isolated polypeptide comprising an amino acid sequence selected from the group consisting of:
- (a) the amino acid sequence of SEQ ID NO:1;
- and,
- (b) a fragment of the amino acid sequence of shown in SEQ ID NO:1, wherein the fragment is at least 15 amino acids in length, and wherein the fragment is functionally equivalent to the polypeptide having the amino acid sequence of SEQ ID NO:1;
- wherein the isolated polypeptide does not have the amino acid sequence of SEQ ID NO:3 or SEQ ID NO:7, and
- an isolated polynucleotide comprising a nucleic acid sequence selected from the group consisting of
- (a) the nucleic acid sequence of SEQ ID NO:2;
- (b) a nucleic acid sequence which is complementary to the nucleic acid sequence of SEQ ID NO:2;
- (c) a nucleic acid sequence which encodes the amino acid sequence of SEQ ID NO:1;
- and,
- (d) a fragment of the nucleic acid sequence of SEQ ID NO:2, wherein the fragment is at least 45 nucleotides in length, and wherein the fragment encodes a polypeptide that is functionally equivalent to the polypeptide having the amino acid sequence of SEQ ID NO:1;
- wherein the isolated polynucleotide does not have the nucleic acid sequence shown in SEQ ID NO:4 or SEQ ID NO:8.
9 more elements
Dependencies are inferred from the claim text.